At a glance
- Originator Memorial Sloan-Kettering Cancer Center; Pfizer
- Class Antiarrhythmics; Pyridones; Pyrimidines; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors; Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 02 Nov 2001 This compound is still in active development
- 21 Jun 2000 Warner-Lambert has merged with Pfizer